Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [3]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-36775 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Phospho-IRF3 (Ser385) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This antibody detects endogenous protein at a molecular weight of 47 and 55 kDa.
- Concentration
- 1 mg/mL
Submitted references Loss of Zfp335 triggers cGAS/STING-dependent apoptosis of post-β selection thymocytes.
G-quadruplex binders as cytostatic modulators of innate immune genes in cancer cells.
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
Ratiu JJ, Barclay WE, Lin E, Wang Q, Wellford S, Mehta N, Harnois MJ, DiPalma D, Roy S, Contreras AV, Shinohara ML, Wiest D, Zhuang Y
Nature communications 2022 Oct 6;13(1):5901
Nature communications 2022 Oct 6;13(1):5901
G-quadruplex binders as cytostatic modulators of innate immune genes in cancer cells.
Miglietta G, Russo M, Duardo RC, Capranico G
Nucleic acids research 2021 Jul 9;49(12):6673-6686
Nucleic acids research 2021 Jul 9;49(12):6673-6686
Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity.
von Roemeling CA, Wang Y, Qie Y, Yuan H, Zhao H, Liu X, Yang Z, Yang M, Deng W, Bruno KA, Chan CK, Lee AS, Rosenfeld SS, Yun K, Johnson AJ, Mitchell DA, Jiang W, Kim BYS
Nature communications 2020 Mar 20;11(1):1508
Nature communications 2020 Mar 20;11(1):1508
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-IRF3 (Ser385) in Lane 1: HeLa cell lysate treated with PMA (100 nM,15mins), Lane 2: Raw264.7 cell lysate treated with PMA (100 nM,15mins), Lane 3: PC12 cell lysate treated with PMA (100 nM,15mins). Samples were incubated with Phospho-IRF3 (Ser385) polyclonal antibody (Product # PA5-36775) at a dilution of 1:500.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-IRF3 pSer385 using Phospho-IRF3 pSer385 polyclonal antibody (Product # PA5-36775) at a dilution of 1:500. Lane 1: Hela cell lysate treated with PMA (100nM, 15min), Lane 2: Raw264.7 cell lysate treated with PMA (100nM, 15min), Lane 3: PC12 cell lysate treated with PMA (100nM, 15min).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis was performed on nuclear enriched cell extracts (30 µg lysate) of THP1 (Lane 1), THP1 treated with TPA (80nM for 16h) followed by LPS (1 µg/mL for 60m) and THP1 treated with TPA (80nM for 16h) followed by transfection with Poly (dA:dT) (5 µg/mL for 3h). The blot was probed with Anti-Phospho-IRF3 (Ser385) Polyclonal Antibody (Product # PA5-36775, 1:1000 dilution) and detected by chemiluminescence using Goat anti-Rabbit IgG (H+L) Superclonal™ Secondary Antibody, HRP conjugate (Product # A27036, 0.25 µg/mL, 1:4000 dilution). A 50kDa band corresponding to Phospho-IRF3 (Ser385) was observed to be induced upon treatment of THP1 cells with TPA with LPS and TPA with poly (dA:dT) treatment.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of Phospho-IRF3 (Ser385) in paraffin-embedded human colon carcinoma and breast carcinoma tissue. Samples were incubated with Phospho-IRF3 (Ser385) polyclonal antibody (Product # PA5-36775).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 4 cGAS-STING pathway is essential for TMZ and anti-CD47 induced immune response. a Combination TMZ and anti-CD47 antibody treatment against murine GBM cells (GL261) increased the production of type I interferons in APCs. IFNA interferon alpha , IFNB interferon beta . n = 5, ** p < 0.01, one-side ANOVA with Bonferroni post hoc correction. b Western blot showing combined TMZ and anti-CD47 antibody treatment resulted in the activation of cGAS-STING cytoplasmic DNA sensing pathways in BM APCs. c Combination TMZ and anti-CD47 antibody treatment promoted p65 expression and nuclear translocation in BM APCs that is dependent on STING. d STING activation is critical to the increased the production of NF-kappaB cytokine TNFalpha and IL1beta in APCs in the setting of combined TMZ and anti-CD47 antibody treatment. n = 6, ** p < 0.01, unpaired Student's t test. e Immunofluorescence staining of GL261 tumors implanted in WT and STING KO animals. Nuclear p-IRF3 (Ser 396) in CD45 + cells is indicative of STING signaling activation. f , g Quantification of CD45 + cell infiltration and percentage of p-IRF3 positive CD45 + , C57BL/6, n = 7; knockout, n = 6. Unpaired Student's t test. h GL261 tumor volume in C57BL/6 or STING KO mice at day 20 following control or combination TMZ + aCD47 treatment, n = 5/group. i T-cell infiltration in GL261 tumors in C57BL/6 or STING KO mice at day 20 following control or combination TMZ + aCD47 treatment measured by CD3 + cells in total DAPI count per field